Based on Your Reading:
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Mesothelioma immunotherapy is a targeted anti-cancer treatment. It utilizes or modifies cells from a patient’s immune system.
In 2020, the U.S. Food and Drug Administration approved Opdivo and Yervoy for mesothelioma. These drugs are generically known as nivolumab and ipilimumab. This treatment for mesothelioma helps the immune system in recognizing cancer cells. It stimulates the production of T cells.
Immunotherapy for mesothelioma cancer has extended the life expectancy of some patients by almost a year. For example, pembrolizumab was the first FDA-approved immunotherapy for mesothelioma patients. Known by the brand name Keytruda, it helped patients with advanced or metastatic disease. Success rates for immunotherapy treatments vary for each patient.
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Mesothelioma immunotherapy works by modifying and improving the immune system. It improves the ability to recognize and kill cancer cells. This process is similar to how the body fights foreign pathogens such as viruses and bacteria that cause disease. Immune cells also help remove other cells that get damaged or have died.
Active immunity occurs when the body creates antibodies. Passive immunity involves artificial immune cells that provide protection. Active immunotherapies help the immune system remember how to produce anti-cancer antibodies. This decreases the cancer recurrence rate. Examples of active immunotherapy include cancer vaccines or CAR T-cell therapy.
Passive immunotherapy has no lasting immunologic memory. Once you stop treatment, the anti-cancer effects of the immune system fade over time. These treatments do not stimulate the body to create long-lasting antibodies. Examples include immune checkpoint inhibitors or cytokines.
Patients should weigh the benefits and risks of active or passive immunotherapy options. For example, cancer vaccines are most effective at preventing cancer from returning after success with other treatments. Immune checkpoint inhibitors are very effective for some mesothelioma patients but can cause severe side effects.
There are several types of immunotherapy for mesothelioma. They include immune checkpoint inhibitors, cancer vaccines, monoclonal antibodies and CAR T-cell therapy. Eligibility varies based on the cancer stage and previous treatment history.
Clinical trials examine the safety and effectiveness of new types of mesothelioma immunotherapy. As a result, immune checkpoint inhibitors have become treatment options for mesothelioma.
Cancer vaccines work like vaccines for the flu and other illnesses by helping prevent specific diseases from coming back. There are two types of cancer vaccines: Preventative and therapeutic. Preventative vaccines decrease the chance of recurrent cancer, and therapeutic vaccines attempt to treat active diseases.
One preventative mesothelioma vaccine targets the OX40 receptor. It has led to decreased tumor growth and increased survival in mice carrying mesothelioma tumors. Researchers are studying whether this vaccine could prevent mesothelioma recurrence.
Two therapeutic vaccines for mesothelioma, the listeria-based cancer vaccine CRS-207 and galinpepimut-S (WT1), have shown promise in clinical trials. A phase II trial of the WT1 vaccine reported longer survival and better tumor control.
Monoclonal antibody therapy (mAb) is the most common immunotherapy for many cancers. Its use is rare for mesothelioma.
Antibody therapy is a targeted treatment focusing on a single site, called an antigen, within cancer cells or on their surface. The treatment involves making many copies of the effective antibody in a lab and transfusing them to patients.
Tremelimumab is both a monoclonal antibody and an immune checkpoint inhibitor. It is under investigation for mesothelioma.
Amatuximab (MORAb-009) is another monoclonal antibody. It progressed to a phase II clinical trial for mesothelioma patients. Overall survival was 14.8 months, almost 25% longer than the average survival for mesothelioma patients.
Adoptive cell transfer involves transferring whole immune cells into patients. It is under study for use in patients with mesothelioma. This therapy has been successful for advanced melanoma and renal cell carcinoma. Another type of adoptive cell transfer, CAR T-cell therapy, modifies immune system T cells to make them cancer-specific.
A phase I clinical trial injected immune system dendritic cells following chemotherapy. Ten mesothelioma patients treated with cisplatin and pemetrexed tolerated the therapy, and the study’s participants showed strong immune responses.
Cytokines are proteins made by T cells. They coordinate immune responses against cancer and foreign pathogens. Cytokines work independently or as a coordinated attack to kill cancer cells or stop the birth of new cells. Examples include tumor necrosis factor, interferon and interleukin-2.
Currently, the FDA has approved Opdivo and Yervoy for pleural mesothelioma. Others have shown promising anti-cancer activity in recent clinical trials. Newer experimental treatments include immune checkpoint inhibitors for peritoneal mesothelioma. As well as targeted therapies such as the WT1 vaccine.
Keytruda is effective against mesothelioma when cancer recurs after first-line treatment. It has led to an average overall patient survival of 18 months. Opdivo and Yervoy combination immunotherapy is an option for nonsurgical pleural patients.
A 2021 clinical trial found that patients treated with Opdivo and Yervoy had a median overall survival of 18.1 months. Chemotherapy patients survived 14.1 months. The two-year survival rate was 41% for patients treated with the immunotherapy combination. It was only 27% for the chemotherapy group.
The primary benefit of immunotherapy for mesothelioma is longer survival and improved symptoms. This targeted treatment aims only to affect cancer cells. It avoids damaging healthy tissue, unlike chemotherapy or radiation. The side effects of immunotherapy are fewer and often more manageable.
Immunotherapy and other targeted therapies are widely considered the future of cancer treatment for mesothelioma patients. By taking advantage of the natural processes of your immune system, immunotherapy can create long-lasting protection against mesothelioma for many years.
Other benefits of immunotherapy for mesothelioma include personalized treatment and financial support. Some types of immunotherapies are specific to the cancer DNA of individual patients. Immunotherapy available through clinical trials is paid for by the study sponsor.
Side effects of immunotherapy for mesothelioma patients involve a heightened immune response. Examples include fevers or body aches. Some side effects, such as coughing or fatigue, can be more uncomfortable for mesothelioma patients.
Most mesothelioma patients experience only mild side effects with immunotherapy. Doctors monitor whether there is a need to slow or stop treatment. Almost all immunotherapy side effects are reversible with rest or medication. In rare cases, more severe reactions can damage sensitive tissue or organs.
Serious side effects can occur when the immune system overproduces antibodies that accumulate in delicate organs such as the lungs or kidneys. Generally these conditions are associated with inflammation, which can cause scarring or organ damage after long periods of time.
Early treatment of immunotherapy side effects can help prevent long-term damage. In every patient’s case, it’s essential to discuss with a mesothelioma specialist the potential benefits versus risks of treatment. Lifestyle changes and habits, such as a mesothelioma diet, can improve energy and reduce the severity of some side effects.
The cost of immunotherapy for mesothelioma patients can be prohibitively expensive for many people, often costing over $10,000 per month. According to a recent Reuters report, Yervoy and Opdivo combination therapy can cost more than $250,000 annually. Other immune checkpoint inhibitors can cost roughly $150,000 per year.
Medicare and many insurance plans cover cancer immunotherapy, but out-of-pocket expenses and lost wages can significantly impact personal finances. VA benefits cover immunotherapy with limited to no out-of-pocket fees, but the veterans claims system can be complicated.
Patient Advocates can help patients and their families identify financial assistance opportunities for medical care, such as clinical trials or legal compensation. The Veterans Outreach team at The Mesothelioma Center can also help patients file VA claims.
Immunotherapy for mesothelioma in the future will likely involve a combination with other cancer therapies. For example, a 2023 study in the Journal of Clinical Oncology showed patient survival benefits in pairing Keytruda with chemotherapy. Other combinations could improve survival for more patients.
Future immunotherapy options for mesothelioma could include tumor-infiltrating lymphocytes, a type of white blood cell that invades tumors. This therapy signals a broader immune response alongside other treatments and may improve mesothelioma prognosis. Advanced preventative vaccines could disrupt the ability of asbestos to cause cancer, reducing risk after exposure.
Mesothelioma specialists provide access to the latest experimental immunotherapies through matching clinical trials or compassionate use programs. The recent FDA approval of Keytruda, Opdivo and Yervoy to treat mesothelioma represents the first steps in the broader availability of immunotherapy options.
Immunotherapy is an experimental mesothelioma treatment option. Clinical research trials are currently ongoing to test the safety and effectiveness of this new therapy. Immunotherapy boosts a patient’s immune system to help treat cancer and works in conjunction with chemotherapy, surgery and other treatments.
Immunotherapy success varies for each patient based on the type and stage of cancer and the patient’s immune system. Pembrolizumab (Keytruda) is one of the most promising immunotherapy options for malignant pleural mesothelioma. In many cases, Keytruda has extended the life expectancy of patients by almost a year.
A systematic review and meta-analysis of 20 studies published in 2018 in Lancet Oncology included 11,351 people with various types of metastatic cancer. Researchers reported men receiving checkpoint inhibitors had a 28% reduced risk of dying during the study period vs a 14% reduced risk for women.
However, a July 2020 report in Biomedicines found that there was an overall survival benefit of immunotherapy for both men and women. No statistically significant difference between men and women’s responses to immunotherapy were found.
Immunotherapy results vary because treatment is predominantly dependent on the activity of the patient’s immune system and the presence of biomarkers on the tumor’s surface. Mesothelioma symptoms and treatment side effects may also be more severe in some patients based on the intensity of the immune reaction.
There are advantages and disadvantages to each treatment. Some patients might have fewer side effects with immunotherapy, while chemotherapy for mesothelioma may better control their tumor growth. Many oncologists use a combination approach that employs both therapies for optimal impact.
We will help you find the best mesothelioma doctor in your area. Our Patient Advocates have relationships with top doctors and cancer centers and can help you schedule and expedite appointments.